Abstract
REPORT HIGHLIGHTS
The global pulmonary drug delivery technologies market which was $19.6 billion
in 2010 is expected to be around $22.5 billion by 2011. This global market is
further projected to reach nearly $44 billion by 2016 at a compound annual
growth rate (CAGR) of 14.3%.
The market for metered dose inhalers (MDIs) was $12.5 billion in 2010 and will
reach $14.4 billion by the end of 2011. BCC forecasts this market will grow to
$29.8 billion by 2016 at a CAGR of 15.7%.
The market for dry powder inhalers (DPIs) was $6.6 billion in 2010. This
market is expected to increase to $7.5 billion in 2011 and reach $13.4 billion
by 2016 at a CAGR of 12.3%.
REPORT SCOPE
INTRODUCTION
STUDY GOALS AND OBJECTIVES
This BCC market research report, Pulmonary Drug Delivery Systems: Technologies
and Global Markets, provides a detailed overview and thorough analysis of the
present and future global market for pulmonary drug delivery technologies.
This report analyzes in detail the pulmonary drug delivery technologies that
are available and currently used and their markets. This report includes
products in this market and detailed analyses of the markets and competitive
environments. It also analyzes current and future market prospects. The
report provides a comprehensive review of emerging pulmonary drug delivery
technologies, particularly with regard to inhaled drug delivery systems. The
analysis reviews technological developments, product innovations, and recent
strategic industry activities of major players across different product
categories. It reviews their strengths and weaknesses, opportunities, and the
threats facing various devices and drugs in this market space. The report
also reviews developments already on the market, major issues involved in the
research and development (R&D) of more effective devices for drug delivery to
the lungs, and new products in development.
REASONS FOR DOING THE STUDY
Pulmonary drug delivery has emerged as a more relevant alternative for
delivering drugs. Respiratory conditions such as asthma, chronic obstructive
pulmonary, and emphysema disease are therapeutic areas of the pulmonary
sector. However, recent technological advancements have applied the
application of pulmonary devices to the treatment of nonrespiratory conditions
such diabetes and migraines. Advancements in formulating technology are
expected to push sales of dry powder inhalers, replacing metered-dose inhalers
to a large extent. Pulmonary delivery of drugs for the treatment of
respiratory diseases stems from the fact that topical drug deposition to the
infected lung gives a fast therapeutic effect and reduces side effects
associated with key drugs. There is a need to understand the trends in this
market, currently available devices and their problems, and the latest
developments for drug delivery to the lungs.
SCOPE AND FORMAT
The report reviews global markets for drug delivery technologies and new
developments, and forecasts trends for use of current devices for drug
delivery and for safety and toxicology through 2016. The report presents
important devices, technologies, and the latest developments, market share by
device and disease type, current products on the market, market share by
company or product, and statistical information for types of respiratory
diseases prevalent worldwide, with special emphasis on the U.S. market. The
report also includes current issues and trends affecting the industry
including costs, and factors influencing demand will be discussed. The report
covers products in development, new technologies, trends, alliances, patents,
and mergers. The report offers market data with respect to segments and
geography. It also provides market trends with respect to drivers,
restraints, and opportunities.
INTENDED AUDIENCE
This report is an exhaustive study of the worldwide drug delivery market,
giving crucial statistics and analysis on existing technologies, the latest
trends, market structure, market size, key drug segments, important trends in
technology development, major opportunities, and market shares of key players
and drugs. This report may prove crucial for drug development companies in
drug delivery space, potential investors in the concerned sector. This
report shows devices currently being used for drug delivery to the lungs, new
developments, spending trends, and revenue prospects for these technologies.
The report provides market data for 2010 to 2016 and also covers commercial
prospects for pulmonary devices and current inhalers in use and their future.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this
report. Secondary sources include books, newspapers, trade journals, white
papers, industry portals, government agencies, trade associations, industry
news, and developments and access to paid databases. The base year of the
report is 2010, with forecast data provided through 2016. Historical, base
year, and forecast data are provided for each market segment of this report.
The report provides a comprehensive review of emerging drug delivery
technologies, particularly with regard to inhaled drug delivery systems. The
new analysis reviews technological developments, product
innovations/introductions, and recent strategic industry activities of major
players across various product categories. Growth rates are determined
through a compilation of data, including past trends, future trends,
demographics, incidence, mortality, products in R&D, and current product
growth.
ANALYST CREDENTIALS
Usha Nagavarapu is an experienced pharmaceutical professional with scientific
and alliance development experience. She has more than 10 years of drug and
device product development and alliance management experience. She has
managed preclinical discovery programs from target identification through
design of Phase I testing, including Investigational New Drug (IND)-enabling
studies, and assisted out-licensing and portfolio development activities.
Strong focus areas include oncology, dermatology, and cardiovascular diseases.
She also has extensive experience working with early startups to fulfill
operational obligations while minimizing overall operational cost and burdens.
BCC ON-LINE SERVICES
BCC Research offers an online information retrieval service. Its home page,
located at www.bccresearch.com, enables readers to:
- Examine the complete BCC Research catalog of market research reports and
place direct orders
- Subscribe to any of BCC Research's many industry newsletters
- Read announcements of recently published reports and newly launched
newsletters
- Register for its well-known conferences
- Request additional information on any BCC research product
- Take advantage of special offers.
DISCLAIMER
The information developed in this report is intended to be as reliable as
possible at the time of publication and of a professional nature. This
information does not constitute managerial, legal, or accounting advice, nor
should it serve as a corporate policy guide, laboratory manual, or an
endorsement of any product, as much of the information is of a speculative
nature. The author assumes no responsibility for any loss or damage that
might result from reliance on the reported information or from its use.
Table of Contents
Chapter- 1: INTRODUCTION - Complimentary
- STUDY GOALS AND OBJECTIVES
- REASONS FOR DOING THE STUDY
- SCOPE AND FORMAT
- INTENDED AUDIENCE
- METHODOLOGY
- RELATED BCC STUDIES
- ANALYST CREDENTIALS
- BCC ON-LINE SERVICES
- DISCLAIMER
Chapter- 2: SUMMARY
- Table 0 : GLOBAL MARKET FOR PULMONARY DRUG DELIVERY TECHNOLOGIES, THROUGH
2016
- Figure 0 : GLOBAL MARKET FOR PULMONARY DRUG DELIVERY TECHNOLOGIES, 2010 -
2016
Chapter- 3: OVERVIEW
- TECHNOLOGY TRENDS
- PULMONARY DRUG DELIVERY
Chapter- 4: PULMONARY DRUG DELIVERY SYSTEM
- BENEFITS OF PULMONARY DRUG DELIVERY SYSTEMS
Chapter- 5: PULMONARY DRUG DELIVERY: DRUGS IN USE
- CURRENT INHALATION DRUGS AND MARKET
Chapter- 6: GLOBAL MARKET FOR PULMONARY DRUG DELIVERY TECHNOLOGIES
- GLOBAL RESPIRATORY MARKET
Chapter- 7: GLOBAL MARKET TRENDS
- REGULATORY CHANGES - PULMONARY DRUG DELIVERY HURDLES
Chapter- 8: KEY COMPANIES
Chapter- 9: DEVELOPMENTS AND COLLABORATIONS
- CURRENT AND FUTURE DEVELOPMENTS
- PRODUCTS IN CLINICAL DEVELOPMENT
Chapter- 10: PATENT ANALYSIS
Chapter- 11: REFERENCES
List of Tables
- Summary Table : GLOBAL MARKET FOR PULMONARY DRUG DELIVERY TECHNOLOGIES,
THROUGH 2016
- Table 1 : INHALER DEVICES AND CHARACTERISTICS
- Table 2 : DOSAGE FORMS-INHALERS
- Table 3 : METERED DOSE INHALERS
- Table 4 : DRY POWDER INHALERS
- Table 5 : ASTHMA AND BIOMARKERS
- Table 6 : INHALED STEROIDS (ASTHMA INHALERS)
- Table 7 : SYSTEMIC STEROIDS FOR ASTHMA TREATMENT
- Table 8 : COPD AND LUNG DAMAGE
- Table 9 : COPD DRUGS ON THE MARKET
- Table 10 : INHALED DRUGS AND MARKET OPPORTUNITIES: CURRENT MARKET FOR
INHALED DRUGS
- Table 11 : INHALER DEVICES
- Table 12 : DRUGS AND THERAPEUTIC AGENTS ADMINISTERED BY INHALATION
- Table 13 : BRAND NAME METERED DOSE INHALERS (CORTICOSTEROIDS)
- Table 14 : BRAND NAME METERED DOSE INHALERS (BRONCHODILATORS)
- Table 15 : LIST OF METERED DOSE INHALERS AND INGREDIENTS
- Table 16 : THE SEVEN CFC INHALERS
- Table 17 : TYPES OF DPI DEVICES
- Table 18 : DPIS CURRENTLY ON THE MARKET
- Table 19 : DPI: ADVANTAGES VERSUS DISADVANTAGES
- Table 20 : TYPES OF DRY POWDER INHALERS (DPI)
- Table 21 : NEBULIZERS AND DRUGS
- Table 22 : NEBULIZERS: ADVANTAGES AND DISADVANTAGES
- Table 23 : VIBRATING MESH NEBULIZERS
- Table 24 : THERAPEUTIC AGENTS ADMINISTERED BY INHALATION
- Table 25 : SHORT-ACTING BRONCHODILATOR INHALERS
- Table 26 : LONG-ACTING BRONCHODILATOR INHALERS
- Table 27 : INHALED STEROID MEDICATIONS
- Table 28 : COMBINATION INHALERS
- Table 29 : GLOBAL PHARMACEUTICAL SALES, THROUGH 2016
- Table 30 : TOP 20 PHARMACEUTICAL COMPANIES IN 2011
- Table 31 : TOP 20 PHARMACEUTICAL COMPANIES IN 2010
- Table 32 : TWELVE LARGEST PHARMACEUTICAL COMPANIES IN 2010
- Table 33 : TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2016
- Table 34 : GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2016
- Table 35 : GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2016
- Table 36 : GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, THROUGH 2016
- Table 37 : GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH
2016
- Table 38 : US DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015
- Table 39 : TYPES OF INHALER UNITS SOLD WORLDWIDE, 2007
- Table 40 : GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, THROUGH 2016
- Table 41 : PULMONARY DELIVERY TECHNOLOGIES MARKET IN THE U.S. AND EUROPE,
THROUGH 2016
- Table 42 : MARKET FOR MDI TECHNOLOGIES, THROUGH 2016
- Table 43 : MARKET FOR DPI TECHNOLOGIES, THROUGH 2016
- Table 44 : SALES OF INHALED STEROIDS AND AEROSOL BETA AGONISTS JANUARY TO
JUNE 2007
- Table 45 : DPI DEVICES
- Table 46 : GROWTH AREAS FOR INHALERS
- Table 47 : TOP SELLING INHALERS, 2010
- Table 48 : TOP SELLING DRUGS IN 2010
- Table 49 : GLOBAL RESPIRATORY DEVICE MARKET, THROUGH 2016
- Table 50 : U.S. RESPIRATORY DEVICE MARKET, THROUGH 2016
- Table 51 : GLOBAL MARKET FOR NEBULIZERS, THROUGH 2016
- Table 52 : APPROVED PULMONARY DRUGS IN RECENT YEARS
- Table 53 : AREAS FOR DRUG DELIVERY IMPROVEMENTS
- Table 54 : PULMONARY DRUG DELIVERY TECHNOLOGIES AND KEY PATENTS
List of Figures
- Summary Figure : GLOBAL MARKET FOR PULMONARY DRUG DELIVERY TECHNOLOGIES,
2010 - 2016
- Figure 1 : GLOBAL PHARMACEUTICAL SALES, 2010 - 2016
- Figure 2 : TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2010 - 2016
- Figure 3 : GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2010 - 2016
- Figure 4 : GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, 2010 - 2016
- Figure 5 : GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, 2010 - 2016
- Figure 6 : GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, 2010 -
2016
- Figure 7 : US DRUG DELIVERY TECHNOLOGIES MARKET, 2010 - 2016
- Figure 8 : GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, 2010 - 2016
- Figure 9 : PULMONARY DRUG DELIVERY TECHNOLOGIES MARKET IN THE U.S. AND
EUROPE, 2010 - 2016
- Figure 10 : MARKET FOR MDI TECHNOLOGIES, 2010 - 2016
- Figure 11 : MARKET FOR DPI TECHNOLOGIES, 2010 - 2016
- Figure 12 : GLOBAL RESPIRATORY DEVICE MARKET, 2010 - 2016
- Figure 13 : U.S. RESPIRATORY DEVICES MARKET, 2010 - 2016
- Figure 14 : GLOBAL MARKET FOR NEBULIZERS, 2010 - 2016
